These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manuscript RIAS2 AST for in vivo samples.pdf (1.42 MB)

An Ultrafast and Flexible LC-MS/MS System Paves the Way for Machine Learning Driven Sample Processing and Data Evaluation in Early Drug Discovery

submitted on 11.02.2021, 19:49 and posted on 12.02.2021, 13:11 by Tim Häbe, Christian Späth, Steffen Schrade, Wolfgang Jörg, Roderich Süssmuth, Daniel Bischoff, Andreas Luippold
Rationale: Low speed and flexibility of most LC-MS/MS approaches in early drug discovery delays sample analysis from routine in vivo studies within the same day of measurements. A highthroughput platform for the rapid quantification of drug compounds in various in vivo assays was developed and established in routine bioanalysis. Methods: Automated selection of an efficient and adequate LC method was realized by autonomous sample qualification for ultrafast batch gradients (9 s/sample) or for fast linear gradients (45 s/sample) if samples require chromatography. The hardware and software components of our Rapid and Integrated Analysis System (RIAS) were streamlined for increased analytical throughput via state-of-the-art automation while keeping high analytical quality. Results: Online decision-making was based on a quick assay suitability test (AST) based on a small and dedicated sample set evaluated by two different strategies. 84% of the acquired data points were within ±30% accuracy and 93% of the deviations between the lower limit of quantitation (LLOQ) values were ≤2-fold compared to standard LC-MS/MS systems while speed, flexibility and overall automation was significantly improved. Conclusions: The developed platform provided an analysis time of only 10 min (batch-mode) and 50 min (gradient-mode) per standard pharmacokinetic (PK) study (62 injections). Automation, data evaluation and results handling were optimized to pave the way for machine learning based decision-making regarding the evaluation strategy of the AST


Email Address of Submitting Author


Boehringer Ingelheim Pharma GmbH & Co. KG



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest